Patents by Inventor Graham DONALD
Graham DONALD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132485Abstract: The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target proteins; i.e. via degradation of a target protein/target proteins by the cullin-RING ubiquitin ligase (CRL). Such target protein/target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and/or neurological disorder. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds. Particularly, the compounds of the present invention may degrade proteins associated with cancer, metabolic disorder, infectious disease and/or neurological disorder.Type: ApplicationFiled: October 15, 2021Publication date: April 25, 2024Inventors: Georg WINTER, Cristina MAYOR RUIZ, Stefan KUBICEK, Alastair David Graham DONALD, Grasilda ZENKEVICIUTE
-
Patent number: 10085538Abstract: A hair care appliance including a body having an outer wall and an inner wall, a fluid flow path extending from a fluid inlet to a fluid outlet wherein the fluid outlet is at least partially defined by the inner wall, a heater for heating fluid in the fluid flow path and, a thermistor for measuring the temperature of fluid between the heater and the fluid outlet, wherein the thermistor is retained with respect to a housing and the housing forms part of the inner wall. The housing may comprise a base that engages with the inner wall. The housing may further comprise an arm wherein the arm supports the thermistor and extends radially inwards of the inner wall. The housing may comprise two arms and the thermistor is suspended between the two arms. The inner wall may comprise an aperture into which the housing is inserted.Type: GrantFiled: October 19, 2016Date of Patent: October 2, 2018Assignee: Dyson Technology LimitedInventors: Samuel William Saunders, Graham Donald, Ben Colin Bobillier
-
Patent number: 9725407Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is an ester group; R2 is the side chain of a natural or non-natural alpha-amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.Type: GrantFiled: January 22, 2016Date of Patent: August 8, 2017Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alan Hornsby Davidson, David Festus Charles Moffat, Francesca Ann Day, Alastair David Graham Donald
-
Patent number: 9702470Abstract: A valve arrangement comprises first and second valves mechanically interconnected for synchronous operation with one another so as to be switchable by a single action between first and second fluid flow configurations. The first configuration provides a first path for first fluid to flow from a first inlet to a first outlet and a second path for second fluid to flow from a second inlet to a second outlet. The second configuration provides paths for first fluid to flow from the first inlet to both the first and second outlets while closing the path from the second inlet. In one application, the arrangement allows a convenient method of disinfecting a water-consuming appliance such as a shower.Type: GrantFiled: January 16, 2014Date of Patent: July 11, 2017Assignee: Horne Engineering LimitedInventor: Graham Donald Paul
-
Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters
Patent number: 9636409Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells, as in the following compound:Type: GrantFiled: February 8, 2016Date of Patent: May 2, 2017Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alan Hastings Drummond, Alan Hornsby Davidson, David Festus Charles Moffat, Alastair David Graham Donald, Stephen John Davies -
Publication number: 20170112255Abstract: A hair care appliance including a body having an outer wall and an inner wall, a fluid flow path extending from a fluid inlet to a fluid outlet wherein the fluid outlet is at least partially defined by the inner wall, a heater for heating fluid in the fluid flow path and, a thermistor for measuring the temperature of fluid between the heater and the fluid outlet, wherein the thermistor is retained with respect to a housing and the housing forms part of the inner wall. The housing may comprise a base that engages with the inner wall. The housing may further comprise an arm wherein the arm supports the thermistor and extends radially inwards of the inner wall. The housing may comprise two arms and the thermistor is suspended between the two arms. The inner wall may comprise an aperture into which the housing is inserted.Type: ApplicationFiled: October 19, 2016Publication date: April 27, 2017Applicant: Dyson Technology LimitedInventors: Samuel William SAUNDERS, Graham DONALD, Ben Colin BOBILLIER
-
Publication number: 20160193200Abstract: The invention provides a compound which is (a) a phenylamide derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate, prodrug or solvate thereof: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.Type: ApplicationFiled: March 17, 2016Publication date: July 7, 2016Inventors: Alastair David Graham Donald, Joanne McDermott, Sanjay Ratilal Patel, David Festus Charles Moffat
-
Publication number: 20160151509Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells.Type: ApplicationFiled: February 8, 2016Publication date: June 2, 2016Inventors: Alan Hastings Drummond, Alan Hornsby Davidson, David Festus Charles Moffat, Alastair David Graham Donald, Stephen John Davies, Margaret Struthers Drummond
-
Publication number: 20160137594Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is an ester group; R2 is the side chain of a natural or non-natural alpha-amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.Type: ApplicationFiled: January 22, 2016Publication date: May 19, 2016Inventors: Alan Hornsby DAVIDSON, David Festus Charles MOFFAT, Francesca Ann DAY, Alastair David Graham DONALD
-
Patent number: 9321718Abstract: The invention provides a compound which is (a) a phenylamide derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate, prodrug or solvate thereof: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.Type: GrantFiled: June 10, 2011Date of Patent: April 26, 2016Assignee: CHROMA THERAPEUTICS LTD.Inventors: Alastair David Graham Donald, Joanne McDermott, Sanjay Ratilal Patel, David Festus Charles Moffat
-
Patent number: 9273003Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.Type: GrantFiled: July 7, 2014Date of Patent: March 1, 2016Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Alan Hornsby Davidson, David Festus Charles Moffat, Francesca Ann Day, Alastair David Graham Donald
-
Publication number: 20150369382Abstract: A valve arrangement comprises first and second valves mechanically interconnected for synchronous operation with one another so as to be switchable by a single action between first and second fluid flow configurations. The first configuration provides a first path for first fluid to flow from a first inlet to a first outlet and a second path for second fluid to flow from a second inlet to a second outlet. The second configuration provides paths for first fluid to flow from the first inlet to both the first and second outlets while closing the path from the second inlet. In one application, the arrangement allows a convenient method of disinfecting a water-consuming appliance such as a shower.Type: ApplicationFiled: January 16, 2014Publication date: December 24, 2015Inventor: Graham Donald Paul
-
Patent number: 9133104Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O), —S(?O)2—, —C(?O)O—, —C(O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X2-Q1- or -Q1-X2— wherein X2 is —O—, S— or NRA— wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic rType: GrantFiled: February 13, 2014Date of Patent: September 15, 2015Assignee: Chroma Therapeutics Ltd.Inventors: Alan Hornsby Davidson, Sanjay Ratilal Patel, Francesca Ann Mazzei, Stephen John Davies, Alan Hastings Drummond, David Festus Charles Moffat, Kenneth William John Baker, Alastair David Graham Donald
-
Patent number: 8962825Abstract: Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent —N? or —C?; B is a divalent radical selected from (B1), (B2), (B3), (B4), (B5) and (B6). wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical; and R is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— or (b) a radical of formula R-L1-Y1—(CH2)z—.Type: GrantFiled: October 30, 2006Date of Patent: February 24, 2015Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: David Charles Festus Moffat, Sanjay Ratilal Patel, Francesca Ann Day, Andrew James Belfield, Alistair David Graham Donald, Alan Hornsby Davidson, Alan Hastings Drummond
-
Publication number: 20140323531Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.Type: ApplicationFiled: July 7, 2014Publication date: October 30, 2014Inventors: Alan Hornsby DAVIDSON, David Festus Charles Moffat, Francesca Ann Day, Alastair David Graham Donald
-
Publication number: 20140163042Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(?O), —S(?O)2—, —C(?O)O—, —C(O)NR3—, —C(?S)—NR3, —C(?NH)NR3 or —S(?O)2NR3— wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X2-Q1- or -Q1-X2— wherein X2 is —O—, S— or NRA— wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic rType: ApplicationFiled: February 13, 2014Publication date: June 12, 2014Applicant: Chroma Therapeutics Ltd.Inventors: Alan Hornsby Davidson, Sanjay Ratilal Patel, Francesca Ann Mazzei, Stephen John Davies, Alan Hastings Drummond, David Festus Charles Moffat, Kenneth William John Baker, Alastair David Graham Donald
-
Publication number: 20140155439Abstract: Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ?CH— or ?N—; W is —CH?CH— Or —CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(C?O)—, —S(?O)2—, —C(C?O)O—, —C(C?O)NR?—, —C(?S)—NR?, —C(?NH)NR? or —S(?O)2NR— wherein R? is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)(Alk2)p— wherein in, n, p, Q, AIk1 and AIk2 are as defined in the claims; X1 represents a bond; —C(?O); or —S(?O)2—; —NR4C(?O)—, —C(C?O)NR4—, —NR4C(?O)NR5—, —NR4S(?O)2—, or —S(?O)2NR4— wherein R4 and R5 are independently hydrogen or optionally substituted C1Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: Chroma Therapeutics Ltd.Inventors: Alastair David Graham Donald, David Festus Charles Moffat, Andrew James Belfield, Carl Leslie North, Stewart Andrew Wayne Jones
-
Patent number: 8719133Abstract: The disclosure herein provides a guaranteed rate of return for a guarantee period of a financial account while at the same time providing upward adjustments to the interest rate if there is a corresponding increase in a specified referenced rate. The guaranteed base interest rate is set at the beginning of the guarantee period, which is credited to an account for an initial pre-defined period. Periodically, the then-current referenced rate is compared to a base referenced rate defined at the establishment of the guarantee period. If the referenced rate has increased, the interest rate that will be credited to the account value will increase by an amount that is based on the amount of increase in the referenced rate. If the referenced rate has not changed or has decreased, the interest rate that will be credited to the account value will be the guaranteed base interest rate.Type: GrantFiled: September 27, 2012Date of Patent: May 6, 2014Assignee: Allstate Insurance CompanyInventors: Donald Paul Abbs, Graham Donald Ireland
-
Patent number: 8686032Abstract: Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers:Type: GrantFiled: December 1, 2010Date of Patent: April 1, 2014Assignee: Chroma Therapeutics Ltd.Inventors: Alan Hornsby Davidson, Sanjay Ratilal Patel, Francesca Ann Mazzei, Stephen John Davies, Alan Hastings Drummond, David Festus Moffat, Kenneth William John Baker, Alistair David Graham Donald
-
Publication number: 20140088159Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: Chroma Therapeutics Ltd.Inventors: Alan Hastings Drummond, Alan Hornsby Davidson, David Festus Charles Moffat, Alastair David Graham Donald, Stephen John Davies